Pharmaceutical News

RSS

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

FDA approves Amphastar's ANDA for Enoxaparin Sodium Injection

Watson Pharmaceuticals, Inc. today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths.

20 Sep 2011

Revolution in drug discovery underway in West Midlands, UK

A revolution in the drug discovery industry is underway, with universities across the West Midlands leading the effort by working in partnership with industry to focus on improving patient care.

19 Sep 2011

Too many kids poisoned with prescription drugs: Study

Figures show that each year half a million kids age 5 and younger get into household medications and are poisoned. Though parents tend to believe that these tragic accidents will never happen to their kids, Dr. Randall Bond, a leading advocate for better prescription drug safety in the home, believes it can happen to anyone.

19 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

Amneal announces availability of generic antiepileptic drug, Felbamate

Amneal Pharmaceuticals, LLC is pleased to announce that its generic Felbamate tablets are now available in 400 mg and 600 mg strengths. Amneal's latest First-to-Market product is an AB-rated, therapeutically equivalent alternative to the antiepileptic drug Felbatol. Annual U.S. sales of Felbatol® are $43.7 million according to January 2011 IMS Health market data.

19 Sep 2011

Meda acquires exclusive licensing rights to Nalox from Moberg Derma

Meda has acquired exclusive licensing rights to Nalox (treatment of fungal nail infections/nail psoriasis) from Moberg Derma AB.

19 Sep 2011

Alkermes establishes business operations in Ireland

Alkermes plc today announced the establishment of its corporate operations in Ireland, with new headquarters located in Dublin. The company, including its headquarters and operations in Athlone, County Westmeath, has more than 450 employees based in Ireland and more than 1,200 employees worldwide.

19 Sep 2011

Low-dose anticholinergic drugs do not appear to cause cognitive impairment in dementia patients

Researchers whose findings on the detrimental impact of some common medicines on elderly people were widely reported earlier in the summer have found that taking a few of these medicines does not appear to cause further cognitive impairment in those already suffering from dementia.

19 Sep 2011

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.

19 Sep 2011

Meda, Moberg Derma enter license agreement for Nalox to treat onychomycosis

Moberg Derma AB and Meda AB have entered into a license agreement covering rights for Nalox - Moberg Derma's patented product for the treatment of discolored and damaged nails caused by nail fungus or nail psoriasis.

19 Sep 2011

Safety tips to prevent unintentional pediatric medication poisonings

A study discussing the dramatic increase in the number of children being poisoned by unintentionally ingesting medications was published online today in the Journal of Pediatrics.

19 Sep 2011

Two newer Type 2 diabetes drugs could be linked to increased risk of pancreatic cancer

Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study.

19 Sep 2011

Bioethicists up the ante in Bachmann's HPV brouhaha

Since Monday's GOP presidential primary debate, Michele Bachmann, a Republican candidate, has been under the microscope for criticizing fellow GOP hopeful Rick Perry for his policy in Texas requiring girls to get the Gardisil vaccine against HPV. Now, two bioethicists have offered cash prizes if she can prove a claim she made about the vaccine's link to mental retardation.

17 Sep 2011

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

Vaxin Inc., a clinical stage vaccine development company, today announced that it has been awarded a contract valued at up to $21.7 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) for pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an IND filing and first-in-man dose ranging study of the company's proprietary anthrax vaccine, AdVAV.

17 Sep 2011

Anti-nausea drug Zofran being tested for its potential heart rhythm side effects

The United States health regulators Food and Drug Administration (FDA) are looking at the safety of GlaxoSmithKline's anti-nausea drug Zofran generically known as ondansetron, to ascertain whether there is a potential risk of abnormal heart rhythm.

16 Sep 2011

DryDiapersPlus joins Unique Wellness and BIOTX to provide incontinence products

DryDiapersPlus is excited to announce that they have joined with Unique Wellness and BIOTX Ltd to provide world-class incontinence products for their customers.

16 Sep 2011

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

The advanced development of a novel next-generation anthrax vaccine and a new type of anthrax antitoxin have received support through new contracts funded the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

16 Sep 2011

Researchers develop polymers that fluoresce in the presence of bacteria

Researchers at the University of Sheffield have developed polymers that fluoresce in the presence of bacteria, paving the way for the rapid detection and assessment of wound infection using ultra-violet light.

16 Sep 2011